Navigation Links
Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
Date:8/12/2009

CRANBURY, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without blood pressure side effects. Based on the positive results of this study, Palatin has scheduled a meeting with the U.S. Food and Drug Administration to discuss initiation of a Phase 2B study of subcutaneously administered bremelanotide for ED.

"This study supports our hypothesis that increases in blood pressure and gastrointestinal events seen with intranasally administered bremelanotide were primarily related to high plasma levels in a subset of patients. We believe this was due to variability in drug uptake with intranasal administration," said Trevor Hallam, Ph.D., Executive Vice President of Research and Development of Palatin. "The switch from intranasal to subcutaneous administration appears to address the blood pressure concerns raised by the FDA. Our next step is to put this data in front of the FDA as we prepare to move bremelanotide back into a Phase 2 study later this year."

Key Results

In all subjects, subcutaneous administration of bremelanotide resulted in consistent and predictable plasma concentrations at levels known from previous studies to improve erectile function. Other key results include:

  • No statistically significant difference in mean changes in blood pressure was seen in subjects receiving bremelanotide compared to placebo.
  • No clinically or statistically significant difference in the range of
    '/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
11. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... EPFL and the University of  Geneva ... John P. Donoghue . The American neuroscientist is ... . The new Wyss Center for Bio- ... Geneva , has named as its director one ... Donoghue , founder of Brown University,s Institute for Brain ...
(Date:7/10/2014)... Women in the West African ... additional family planning option. Sayana® Press has the ... levels of the health system and in communities ... used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the BD ... first of four African countries expected to begin ...
(Date:7/10/2014)... 2014 Terascala, the industry leader in ... Swahn, a former vice president of product management for ... president of marketing. Terascala’s software when combined with leading ... the highest performance and most reliable solutions for processing ... Terascala’s channel expansion and broaden its product portfolio. His ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... 16 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that ... with Abbott for the exclusive worldwide development and commercialization of elagolix and the ... , The live ... at 8:45 a.m. Eastern Time ( 5:45 a.m. Pacific Time ...
... ... for certifying dentists in a new denture retention system procedure that can add 20% profit to ... (PRWEB) June 16, ... in a new denture retention system procedure that can add 20% profit to a ...
... American ... ... Association named medical writer, Rita Buckley, Writer/Owner of medical writing firm Buckley/Swartz, ... the awards for The Lehman Series Expert Panel on Weight Loss Surgery, published in ...
Cached Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix 2Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 2Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 3Summit Dental Institute Offers A Hands-On One-Day Imtec MDI Mini Dental Implant Certification Course For Dentists 4Medical Writer Rita Buckley Wins Awards for Excellence in Medical Communication 2Medical Writer Rita Buckley Wins Awards for Excellence in Medical Communication 3
(Date:7/10/2014)... YORK , June 27, 2014  Pomerantz ... Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) ... filed in United States District Court, Middle District ... is on behalf of a class consisting of ... acquired Provectus securities between December 17, 2013 and ...
(Date:7/10/2014)... -- NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the ... was interviewed on July 1 st on the ... . Mr. Pereira discusses the company,s next generation smart wallet ... the Wocket™ aims to replace a traditional wallet with a ... tells Gino he has never heard of the Wocket ...
(Date:7/10/2014)... GOTHENBURG, Sweden , July 8, 2014 ... FPC1021 has won a new design win (DW). An Asian ... targeted date for mass production start in August 2014.   ... an Asian smartphone OEM, which has a planned date for ... received an initial ramp order of SEK 5M, for delivery ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... Laboratories researchers competing in an international pool of ... R&D 100 Awards in this year,s contest, and were ... awards each year to researchers whom its editors and ... most outstanding advances in applied technologies. The awards, ...
... TORONTO, ON A new study by psychologists at the ... can more accurately identify a man,s sexual orientation when looking ... of peak ovulation. Further, having romantic thoughts or a mating ... gay men. "This effect is not apparent when a ...
... in states such as Massachusetts, Wisconsin, New Jersey, Washington, ... for growers trying to realize profits in heavy cranberry ... damage can have a particularly significant negative impact in ... preferences of insects, entomologists have reported that several insects ...
Cached Biology News:Sandia captures 4 R&D 100 Awards 2Sandia captures 4 R&D 100 Awards 3Psychologists find link between ovulation and women's ability to identify heterosexual men 2Pest preferences for cranberry cultivars determined 2
Request Info...
... include: ,ICC and IHC Protocol Development ... ,Antibody Screenings in Animal or Human ... of Cells and Tissues ,Peroxidase, Alkaline ... Fluorescent, or Electron Microscopy ,Protein Localization ...
Request Info...
Request Info...
Biology Products: